BioDelivery Sciences risk/reward profile favorable, says William Blair William Blair reiterates an Outperform rating on shares of BioDelivery Sciences ahead of the June 7 PDUFA date for Bunavail, the company's buprenorphine/naloxone sublingual film for the treatment of opioid addiction. The firm says the FDA has been focused on new therapies for opioid addiction given the current opioid-abuse crisis. It views the risk/reward for BioDelivery shares as favorable and has a $16 price target for the stock.
On The Fly: After Hours Movers UP AFTER EARNINGS: Progress Software (PRGS), up 6.6%. ALSO HIGHER: Xoom (XOOM), up 22% after announcing company to be acquired by PayPal... BioDelivery Sciences (BDSI), up 4.7% after Point72 Asset Management reports 5.5% passive stake in the company... Green Brick Partners (GRBK), up 7.5% after Third Point reports 16.9% stake in the company.